In conversation with Steve Paul, CEO of Karuna Therapeutics by Amirah Al Idrus Thursday, January 16, 2020 Steven Paul, M.D., left Eli Lilly after 17 years to “do something a bit more entrepreneurial." He went on to work on CNS disorders in small biotechs.
Eli Lilly ditches NextCure pact by Ben Adams Monday, January 13, 2020 Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago.
Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout by Nick Paul Taylor Friday, January 10, 2020 The takeover, which values Dermira at just a whisker above its closing price yesterday, comes months after the biotech posted phase 2b data.
Aduro's staffers feel the sting after Novartis walks by Ben Adams Friday, January 10, 2020 It’s grim news ahead of the J.P. Morgan Healthcare Conference next week for Aduro Biotech.
Pfizer's Read picks up position at new firm—Chutes & Ladders by Kyle Blankenship Friday, January 10, 2020 Pfizer ex-CEO Read picks up job at The Carlyle Group; AMAG dumps CEO Heiden; ex-Lilly chief Conterno joins team at Fibrogen.
Is there a future for pharma in neuro? by Nick Paul Taylor Friday, December 20, 2019 The retreat of big biopharma from neuroscience R&D continued apace in 2019, with Amgen axing its neuroscience unit and Eli Lilly shuttering a U.K. fac
30. Reyvow by Ben Adams Reyvow, a first-in-class drug Lilly picked up with its 2017 CoLucid buyout, won approval in the fall to treat migraines as they occur.
Lilly plots 'ambitious' cancer program after sharing early data by Nick Paul Taylor Sunday, December 8, 2019 Lilly unveiled early clinical data on the BTK inhibitor it acquired with Loxo Oncology—and the numbers are strong enough to prompt some action.
Lilly rejigs cancer R&D—and puts Loxo team in charge by Amirah Al Idrus Thursday, December 5, 2019 Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.
Novo Nordisk, Dicerna ink $225M metabolic, liver disease deal by Amirah Al Idrus Monday, November 18, 2019 Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis, to the tune of $225 million.
